APRI (Aprinoia Therapeutics) Other Long-Term Liabilities: $65.88 Mil (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics Other Long-Term Liabilities?

Aprinoia Therapeutics APRI Other Long-Term Liabilities is $65.88 Mil as of Dec. 2023.

Aprinoia Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2023 was $65.88 Mil.

Aprinoia Therapeutics's quarterly other long-term liabilities stayed the same from Dec. 2022 ($65.88 Mil) to Jun. 2023 ($65.88 Mil) and stayed the same from Jun. 2023 ($65.88 Mil) to Dec. 2023 ($65.88 Mil).

Aprinoia Therapeutics's annual other long-term liabilities increased from Dec. 2021 ($56.91 Mil) to Dec. 2022 ($65.88 Mil) but then stayed the same from Dec. 2022 ($65.88 Mil) to Dec. 2023 ($65.88 Mil).

Aprinoia Therapeutics Other Long-Term Liabilities Related Terms

Aprinoia Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Other Long-Term Liabilities Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Long-Term Liabilities
56.91 65.88 65.88

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Other Long-Term Liabilities 56.91 0.00 65.88 65.88 65.88

Aprinoia Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $65.88 Mil mean?
Aprinoia Therapeutics (APRI) has a Other Long-Term Liabilities of $65.88 Mil as of Dec. 2023. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Other Long-Term Liabilities too high?
Aprinoia Therapeutics' current Other Long-Term Liabilities is $65.88 Mil.
How does Aprinoia Therapeutics' Other Long-Term Liabilities compare to ?
Aprinoia Therapeutics' Other Long-Term Liabilities of $65.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Other Long-Term Liabilities is $65.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Other Long-Term Liabilities of $65.88 Mil. The current Other Long-Term Liabilities is $65.88 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Other Long-Term Liabilities is $65.88 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.